Tips

From Other Journals

Effect of ACE Inhibitors on Nondiabetic Renal Disease



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2002 Mar 1;65(5):951-952.

Patients with renal disease often experience a reduced quality of life with increased morbidity and mortality. The ability of angiotensin-converting enzyme (ACE) inhibitors to slow the progression of renal disease in patients with type 1 and type 2 diabetes is becoming clear. Their efficacy in patients with nondiabetic renal disease is less clear. Jafar and associates pooled data from 11 randomized, controlled studies and compared the effects of antihypertensive regimens with and without ACE inhibitors on renal disease.

All 1,860 study participants had either hypertension or diminished renal function. The ACE inhibitor used varied among studies. All patients received regular blood pressure measurements and laboratory testing. The primary outcomes were end-stage renal disease (ESRD) and a twofold increase in serum creatinine concentration.

The patients treated with ACE inhibitors had a lower rate of ESRD and doubling of the serum creatinine level. The beneficial effect of ACE inhibitors was greater in patients with higher urinary protein excretion. Factors that were independently associated with increased risk of ESRD included younger age, female gender, higher serum creatinine concentration, higher systolic blood pressure and higher urinary protein concentration.

The authors conclude that ACE inhibitors should be the initial antihypertensive treatment in patients with nondiabetic renal disease, especially if proteinuria is greater than 0.5 g per day. This ability to slow the progression of renal disease appears to be independent of successfully lowering the blood pressure or decreasing renal protein excretion.

In an accompanying editorial, Schrier and Estacio discuss the difficulties of using a meta-analysis to make definitive clinical recommendations. Variations in blood pressure control, antihypertensive treatment regimens, and urinary protein excretion in the various trials make data aggregation difficult. Further studies are needed to investigate the value of ACE inhibitor therapy in patients with lower levels of urinary protein excretion. The authors assert that although the conclusion that ACE inhibitors have value in the management of nondiabetic renal disease may be correct, further long-term, randomized, controlled studies are needed.

Jafar TH, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Intern Med July 17, 2001;135:73–87, and Schrier RW, Estacio RO. The effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials [Editorial]. Ann Intern Med. July 17, 2001;135:138–9.


Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article